13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
35 檔
52.5%
During the Q2 2025 filing period, Artia Global Partners LP (CIK: 0001937964) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $541.9M across 35 reported positions.
In Q2 2025, Artia Global Partners LP displayed an active expansion posture, initiating 12 new positions and adding to 9 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 23.12% | — | +88.68% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 19.19% | -18.15% | +149.09% | |
| 3 | ARGX | Argenx Se - Adr | Stock-Healthcare | 10.39% | +0.74% | +592.34% | |
| 4 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 9.97% | -0.46% | EXIT | |
| 5 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.76% | -7.04% | EXIT | |
| 6 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.01% | — | +19.66% | |
| 7 | ✓ | Merus N V | Stock-Other | 3.76% | — | -30.12% | |
| 8 | DGX | Quest Diagnostics Inc | Stock-Healthcare | 3.53% | +0.95% | +44.08% | |
| 9 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 3.21% | — | — | |
| 10 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 2.00% | +2.92% | NEW | |
| 11 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.73% | +2.80% | — | |
| 12 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.65% | — | -26.68% | |
| 13 | UGL | Proshares Ultra Gold | ETF-Commodities | 1.40% | — | — | |
| 14 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 1.35% | — | — | |
| 15 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.08% | +0.03% | -26.66% | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.92% | +3.98% | — | |
| 17 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.72% | — | +18.54% | |
| 18 | EYPT | Eyepoint Inc | Stock-Other | 0.72% | +0.04% | — | |
| 19 | ABBV | Abbvie Inc | Stock-Healthcare | 0.65% | -0.63% | EXIT | |
| 20 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.62% | +0.12% | +6.87% | |
| 21 | ASND | Ascendis Pharma A/S | Stock-Other | 0.51% | -0.81% | EXIT | |
| 22 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.47% | — | — | |
| 23 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 0.47% | — | — | |
| 24 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.37% | — | — | |
| 25 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.35% | -0.09% | — | |
| 26 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.31% | — | +12.82% | |
| 27 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.31% | +0.04% | -93.13% | |
| 28 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.30% | -0.04% | — | |
| 29 | BHVN | Biohaven Ltd. | Stock-Other | 0.27% | — | — | |
| 30 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.24% | — | — | |
| 31 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.19% | +0.06% | — | |
| 32 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.13% | -0.06% | — | |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.12% | -0.08% | — | |
| 34 | JANX | Janux Therapeutics Inc | Stock-Other | 0.11% | — | -47.51% | |
| 35 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.11% | +3.13% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +14.5% | +88.68% | Add |
| 2 | INSM | Insmed Inc | +13.1% | +149.09% | Add |
| 3 | ARGX | Argenx Se - Adr | +8.7% | +592.34% | Add |
| 4 | XBI | Ss Spdr S&p Biotech ETF | +2% | NEW | New buy |
| 5 | TRVI | Trevi Therapeutics Inc | +1.7% | NEW | New buy |
| 6 | UGL | Proshares Ultra Gold | +1.4% | NEW | New buy |
| 7 | REGN | Regeneron Pharmaceuticals | +1.4% | NEW | New buy |
| 8 | DGX | Quest Diagnostics Inc | +1.1% | +44.08% | Add |
| 9 | BSX | Boston Scientific CORP | +0.7% | +19.66% | Add |
| 10 | ABBV | Abbvie Inc | +0.7% | NEW | New buy |
| 11 | VRTX | Vertex Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 12 | RARE | Ultragenyx Pharmaceutical In | +0.4% | NEW | New buy |
| 13 | EYPT | Eyepoint Inc | +0.3% | — | Unchanged |
| 14 | BHVN | Biohaven Ltd. | +0.3% | NEW | New buy |
| 15 | RNAGBP | Avidity Biosciences Inc | +0.2% | NEW | New buy |
| 16 | ASND | Ascendis Pharma A/S | +0.2% | +64.52% | Add |
| 17 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.2% | NEW | New buy |
| 18 | MLYS | Mineralys Therapeutics Inc | +0.1% | NEW | New buy |
| 19 | SWTXUSD | Springworks Therapeutics Inc | +0.1% | +18.54% | Add |
| 20 | NAMS | NewAmsterdam Pharma Company N.V. | +0.1% | NEW | New buy |
| 21 | VKTX | Viking Therapeutics Inc | +0.1% | +6.87% | Add |
| 22 | MREO | Mereo Biopharma Group Pl-adr | +0.1% | +12.82% | Add |
| 23 | RVMD | Revolution Medicines Inc | 0% | — | Unchanged |
| 24 | ORKA | Oruka Therapeutics Inc | 0% | EXIT | Sold out |
| 25 | TVTX | Travere Therapeutics Inc | 0% | — | Unchanged |
| 26 | UTHR | United Therapeutics CORP | 0% | — | Unchanged |
| 27 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Unchanged |
| 28 | TGTX | Tg Therapeutics Inc | -0.1% | — | Unchanged |
| 29 | 260 | Centessa Pharmaceuticals-adr | -0.1% | EXIT | Sold out |
| 30 | JANX | Janux Therapeutics Inc | -0.2% | -47.51% | Trim |
| 31 | ALNY | Alnylam Pharmaceuticals Inc | -0.3% | -26.68% | Trim |
| 32 | SRRK | Scholar Rock Holding CORP | -0.3% | -26.66% | Trim |
| 33 | AZNN | Astrazeneca Plc-spons Adr | -0.3% | — | Unchanged |
| 34 | NBIX | Neurocrine Biosciences Inc | -0.4% | EXIT | Sold out |
| 35 | ISRG | Intuitive Surgical Inc | -0.4% | EXIT | Sold out |
| 36 | VRDN | Viridian Therapeutics Inc | -0.6% | EXIT | Sold out |
| 37 | RYTM | Rhythm Pharmaceuticals Inc | -0.7% | EXIT | Sold out |
| 38 | ✓ | Merus N V | -0.8% | -30.12% | Trim |
| 39 | NUVL | Nuvalent Inc-a | -1.6% | EXIT | Sold out |
| 40 | SLNOEUR | Soleno Therapeutics Inc | -3.3% | -32.77% | Trim |
| 41 | PTGX | Protagonist Therapeutics Inc | -3.8% | -93.13% | Trim |
| 42 | ACLXGBX | Arcellx Inc | -3.8% | EXIT | Sold out |
| 43 | ITCIEUR | Intra-cellular Therapies Inc | -7.3% | EXIT | Sold out |
| 44 | LLY | Eli Lilly & Co | -23.5% | -78.05% | Trim |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 35 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VRNA, INSM, ARGX) accounted for 52.5% of total reported equity market value during Q2 2025.
Top New Position Initiated
XBI
市值: $8.3M
Top Position Liquidated / Trimmed
ITCIEUR
前期市值: $29.0M
During Q2 2025, Artia Global Partners LP's top holdings by market value included VRNA (23.1%)、INSM (19.2%)、ARGX (10.4%). The largest single position, VRNA, represented 23.1% of total portfolio value.
In Q2 2025, Artia Global Partners LP made 37 total portfolio adjustments, initiating 12 new buys, adding to 9 positions, trimming 7 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.